Subtype
Malignant Urinary Tract Neoplasm
CI-CAN-00003252Explore in graph →
507 active trials14 approved drugs29 evidence items
- NCIt
- C192668
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003252Explore in graph →
Clinical trials
1,955 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (246)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04909775 | Chemotherapy Combined With Tislelizumab as Bladder Sparing Option for Patients With Muscle Invasive Bladder Cancer | unknown | Phase 2 | 40 | Ruijin HospitalOTHER | 1 | Jun 2, 2021 | clinicaltrials |
| NCT04878250 | Preoperative Bintrafusp Alfa in Operable Urothelial Carcinoma of the Bladder(PEBBLE) | unknown | Phase 2 | 49 | Queen Mary University of LondonOTHER | 0 | May 7, 2021 | clinicaltrials |
| NCT03664869 | Electromotive Mitomycin-C (EMDA-MMC) in Preventing Recurrences in High-risk Non-muscle-invasive Bladder Cancer(FB10) | unknown | Phase 3 | 300 | Turku University HospitalOTHER_GOV | 1 | Apr 1, 2021 | clinicaltrials |
| NCT04812145 | Role of Hypofractionated Radiotherapy With Concurrent Gemcitabine in Treatment of Urinary Bladder Carcinoma | unknown | — | 50 | Assiut UniversityOTHER | 0 | Mar 23, 2021 | clinicaltrials |
| NCT03824691 | hARnessing CAbozantinib and Durvalumab Immuno-oncology Association: ARCADIA Study"(ARCADIA) | unknown | Phase 2 | 122 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Feb 25, 2021 | clinicaltrials |
| NCT04750590 | Relationship Between Methods of Bladder Tumor Extraction and Local Recurrence Rate | unknown | N/A | 180 | I.M. Sechenov First Moscow State Medical UniversityOTHER | 1 | Feb 21, 2021 | clinicaltrials |
| NCT04305730 | Use of Pedometer Following Radical Cystectomy | unknown | N/A | 35 | Benaroya Research InstituteOTHER | 1 | Feb 16, 2021 | clinicaltrials |
| NCT04756284 | Evaluation of the PhageTech Virus BioResistor | unknown | — | 50 | PhageTech, Inc.INDUSTRY | 1 | Feb 16, 2021 | clinicaltrials |
| NCT04383067 | A Phase 2, Single-Center, Open Label Study of Autologous, Adoptive Cell Therapy Following a Reduced Intensity, Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Urothelial Carcinoma Patients | unknown | Phase 2 | 20 | Sheba Medical CenterOTHER_GOV | 1 | Feb 11, 2021 | clinicaltrials |
| NCT04738630 | Study of HX008 for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer | unknown | Phase 2 | 110 | Taizhou Hanzhong biomedical co. LTDINDUSTRY | 1 | Feb 4, 2021 | clinicaltrials |
| NCT04712201 | En Bloc Bladder Tumor Resection: Prospective Randomized Study | unknown | N/A | 300 | Fundacio PuigvertOTHER | 1 | Jan 15, 2021 | clinicaltrials |
| NCT04687254 | Gender-related Characteristics of Bladder Cancer Treatment(BladderBLOG) | unknown | — | 500 | University of FlorenceOTHER | 1 | Dec 29, 2020 | clinicaltrials |
| NCT04686149 | a Genome-based Platform to Predict Patients That Can Achieve Bladder Preservation in Muscle Invasive Bladder Cancer Patients | unknown | — | 39 | Yonsei UniversityOTHER | 1 | Dec 28, 2020 | clinicaltrials |
| NCT03896958 | The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)(PIONEER) | unknown | — | 1,000 | SpeciCareINDUSTRY | 1 | Dec 4, 2020 | clinicaltrials |
| NCT04523025 | Nordic Cystectomy Study I - Neutrophil-lymphocyte Ratio (NLR)(NorCys-NLR) | unknown | — | 230 | Turku University HospitalOTHER_GOV | 1 | Nov 25, 2020 | clinicaltrials |
| NCT04523038 | Nordic Cystectomy Study II - Albumin(NorCys-Alb) | unknown | — | 1,700 | Turku University HospitalOTHER_GOV | 1 | Nov 25, 2020 | clinicaltrials |
| NCT04537221 | Nordic Cystectomy Study III - Transfusion(NorCys-Transf) | unknown | — | 1,700 | Turku University HospitalOTHER_GOV | 1 | Nov 25, 2020 | clinicaltrials |
| NCT04211012 | A Study on Toripalimab Plus Nab-Paclitaxel With or Without Cisplatin as First-line Treatment of Urothelial Carcinoma | unknown | Phase 2 | 30 | Jun GuoOTHER | 1 | Nov 13, 2020 | clinicaltrials |
| NCT04610385 | Ileal Conduit Versus Cutaneous Ureterostomy After Radical Cystectomy | unknown | — | 40 | Assiut UniversityOTHER | 0 | Oct 30, 2020 | clinicaltrials |
| NCT04402411 | Quadratus Lumborum Block vs Transversus Abdominis Plane Block in Bladder Cancer Surgeries | unknown | N/A | 63 | National Cancer Institute, EgyptOTHER | 1 | Oct 19, 2020 | clinicaltrials |
| NCT04588168 | Multi-parameter Magnetic Resonance Imaging Guides Precise Treatment of Urothelial Carcinoma | unknown | N/A | 100 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Oct 19, 2020 | clinicaltrials |
| NCT03113266 | Safety and Efficacy of Toripalimab for Patients With Locally Advanced or Metastatic Bladder Urothelial Carcinoma | unknown | Phase 2 | 370 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Sep 30, 2020 | clinicaltrials |
| NCT04286672 | Metadherin mRNA Expression in Bladder Cancer | unknown | — | 70 | Assiut UniversityOTHER | 0 | Sep 29, 2020 | clinicaltrials |
| NCT04525781 | Clinicoepidimiological Study and Clinical Outcome in Patients With Urinary Bladder Cancer | unknown | — | 150 | Assiut UniversityOTHER | 0 | Aug 25, 2020 | clinicaltrials |
| NCT04493489 | Propranolol Adjuvant Treatment of Bladder Cancer | unknown | Phase 2 | 242 | Central South UniversityOTHER | 0 | Jul 30, 2020 | clinicaltrials |
| NCT04219046 | Evaluation of Naloxegol in the Prevention of POI After Cystectomy(ANTAGOCYST) | unknown | Phase 2 | 102 | Institut Paoli-CalmettesOTHER | 0 | Jul 28, 2020 | clinicaltrials |
| NCT03254888 | Autophagy Bladder Cancer | unknown | — | 150 | Assiut UniversityOTHER | 1 | Jul 8, 2020 | clinicaltrials |
| NCT04256616 | Immunogenic Cell Death as a Novel Mechanism of Mitomycin C Activity in Bladder Cancer(ICH-MIM-01) | unknown | — | 110 | Istituto Clinico HumanitasOTHER | 1 | Jul 7, 2020 | clinicaltrials |
| NCT04406168 | Assessment of Urinary Diversions Outcomes Post Radical Cystectomy in Asyut University Urology Hospital | unknown | — | 40 | Assiut UniversityOTHER | 1 | May 28, 2020 | clinicaltrials |
| NCT04385316 | Clinical Study of Gastric Cancer, Colorectal Cancer and Bladder Cancer Based on Liquid Biopsy | unknown | — | 3 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | May 12, 2020 | clinicaltrials |
| NCT01993979 | A Phase III Randomised Trial of Peri-Operative Chemotherapy Versus sUrveillance in Upper Tract Urothelial Cancer (POUT)(POUT) | unknown | Phase 3 | 261 | Institute of Cancer Research, United KingdomOTHER | 1 | May 4, 2020 | clinicaltrials |
| NCT02070120 | Investigating Bladder Chemotherapy Instead of Surgery for Low Risk Bladder Cancer(CALIBER) | unknown | Phase 2 | 82 | Institute of Cancer Research, United KingdomOTHER | 1 | Mar 19, 2020 | clinicaltrials |
| NCT04295967 | Vasculogenic Mimicry in Urothelial Carcinoma | unknown | — | 70 | Assiut UniversityOTHER | 0 | Mar 5, 2020 | clinicaltrials |
| NCT04264936 | A Study of RC48-ADC(Antibody Drug Conjugate) and JS001 to Evaluate the Safety and Pharmacokinetics of Subjects With Locally Advanced or Metastatic Urothelial Cancer | unknown | Phase 1 / Phase 2 | 36 | Peking University Cancer Hospital & InstituteOTHER | 1 | Feb 13, 2020 | clinicaltrials |
| NCT03522155 | Patient-Centered Communication of Life Expectancy Estimates in Genitourinary Malignancies | unknown | N/A | 136 | Cedars-Sinai Medical CenterOTHER | 1 | Feb 6, 2020 | clinicaltrials |
| NCT04245618 | Neoadjuvant Chemotherapy in Non Muscle Invasive T1b Bladder Cancer | unknown | — | 50 | Assiut UniversityOTHER | 0 | Jan 30, 2020 | clinicaltrials |
| NCT04228198 | Protocol of the Italian Radical Cystectomy Registry | unknown | — | 1,000 | University of Roma La SapienzaOTHER | 1 | Jan 14, 2020 | clinicaltrials |
| NCT03739177 | Onco4D(TM) Biodynamic Chemotherapy Selection for Bladder Cancer Patients | unknown | — | 150 | Animated Dynamics, Inc.INDUSTRY | 1 | Jan 13, 2020 | clinicaltrials |
| NCT04223063 | Exercise-based Pre-habilitation in Bladder Cancer Patients Prior to Radical Cystectomy: a Feasibility Study | unknown | N/A | 20 | Ross MasonOTHER | 0 | Jan 10, 2020 | clinicaltrials |
| NCT01447199 | The Molecular Predisposition to Hereditary Nonpolyposis Colon Cancer (HNPCC) | unknown | — | 2,000 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 7, 2020 | clinicaltrials |
| NCT04148677 | Protoves M1® Syrup in Controlling Adverse Event During HIVEC® Instillations | unknown | — | 100 | Cardarelli HospitalOTHER | 0 | Nov 1, 2019 | clinicaltrials |
| NCT04129606 | Bladder Perforation Post-TURBT: Definition, Incidence and Natural HistoryStudy(TURBT-BP) | unknown | N/A | 300 | Abdelwahab HashemOTHER | 1 | Oct 17, 2019 | clinicaltrials |
| NCT04060459 | Paclitaxel-binding Albumin and Cisplatin as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer | unknown | Phase 2 | 50 | Third Military Medical UniversityOTHER | 1 | Aug 19, 2019 | clinicaltrials |
| NCT03673202 | The Cxbladder Rule-out of Recurrent Urothelial Carcinoma | unknown | — | 300 | London Health Sciences CentreOTHER | 1 | Aug 14, 2019 | clinicaltrials |
| NCT02292914 | Prospective Analysis of Robot-Assisted Surgery | unknown | N/A | 1,120 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Aug 8, 2019 | clinicaltrials |
| NCT03998371 | Application of UCAD for Diagnosing Urothelial Carcinoma. | unknown | — | 300 | Changhai HospitalOTHER | 1 | Jun 26, 2019 | clinicaltrials |
| NCT03982797 | Treatment of High-risk Non-muscle Invasive Bladder Cancer With IMUNO BGC Moreau RJ as Prophylaxis | unknown | Phase 2 | 306 | Biofabri, S.LINDUSTRY | 1 | Jun 12, 2019 | clinicaltrials |
| NCT03973307 | UroX Biomarker Bladder Cancer Study | unknown | — | 100 | East and North Hertfordshire NHS TrustOTHER_GOV | 1 | Jun 4, 2019 | clinicaltrials |
Data updated 23 days agoSource updated Jun 2, 2021source: clinicaltrials